CD274 and acute myeloid leukemia: Supporting current clinical efforts to bring neoantigen vaccination to hematological cancers [26], Stroopinsky et al. [18] found that an acute myeloid leukemia (AML)-fused DC vaccine overcame tumor resistance to a PD-L1 checkpoint inhibitor therapy in an AML murine model.